117 related articles for article (PubMed ID: 8579739)
1. The use of pronase-digested human leukocytes to improve specificity of the flow cytometric crossmatch.
Lobo PI; Spencer CE; Stevenson WC; McCullough C; Pruett TL
Transpl Int; 1995; 8(6):472-80. PubMed ID: 8579739
[TBL] [Abstract][Full Text] [Related]
2. Improved specificity and sensitivity when using pronase-digested lymphocytes to perform flow-cytometric crossmatch prior to renal transplantation.
Lobo PI; Isaacs RB; Spencer CE; Pruett TL; Sanfey HA; Sawyer RG; McCullough C
Transpl Int; 2002 Nov; 15(11):563-9. PubMed ID: 12461661
[TBL] [Abstract][Full Text] [Related]
3. Improved flow cytometric detection of HLA alloantibodies using pronase: potential implications in renal transplantation.
Vaidya S; Cooper TY; Avandsalehi J; Barnes T; Brooks K; Hymel P; Noor M; Sellers R; Thomas A; Stewart D; Daller J; Fish JC; Gugliuzza KK; Bray RA
Transplantation; 2001 Feb; 71(3):422-8. PubMed ID: 11233905
[TBL] [Abstract][Full Text] [Related]
4. Hyperacute renal allograft rejection from anti-HLA class 1 antibody to B cells--antibody detection by two color FCXM was possible only after using pronase-digested donor lymphocytes.
Lobo PI; Spencer CE; Isaacs RB; McCullough C
Transpl Int; 1997; 10(1):69-73. PubMed ID: 9002156
[TBL] [Abstract][Full Text] [Related]
5. Reanalysis of the role of pronase treatment of B cells in the flow cytometric crossmatch assay: Fc receptor is not the primary target.
Brown NK; Meade JR; Wang J; Marino SR
Hum Immunol; 2017 Nov; 78(11-12):704-709. PubMed ID: 28987959
[TBL] [Abstract][Full Text] [Related]
6. Low Expression Loci and the Use of Pronase in Flow Cytometry Crossmatch.
Silva C; Aires P; Santo P; Xavier P
Transplant Proc; 2023; 55(6):1383-1389. PubMed ID: 37173263
[TBL] [Abstract][Full Text] [Related]
7. Frequent false-positive reactions in pronase-treated T-cell flow cytometric cross-match tests.
Park H; Lim YM; Han BY; Hyun J; Song EY; Park MH
Transplant Proc; 2012 Jan; 44(1):87-90. PubMed ID: 22310587
[TBL] [Abstract][Full Text] [Related]
8. Positive B-cell only flow cytometric crossmatch: implications for renal transplantation.
Delgado JC; Eckels DD
Exp Mol Pathol; 2008 Aug; 85(1):59-63. PubMed ID: 18499103
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometry crossmatch reactivity with pronase-treated T cells induced by non-HLA autoantibodies in human immunodeficiency virus-infected patients.
Szewczyk K; Barrios K; Magas D; Sieg K; Labuda B; Jendrisak MD; Jaramillo A
Hum Immunol; 2016 Jun; 77(6):449-55. PubMed ID: 27094930
[TBL] [Abstract][Full Text] [Related]
10. Impact of rituximab on the T-cell flow cytometric crossmatch.
Doss SA; Mittal S; Daniel D
Transpl Immunol; 2021 Feb; 64():101360. PubMed ID: 33359130
[TBL] [Abstract][Full Text] [Related]
11. The flow cytometric crossmatch. Dual-color analysis of T cell and B cell reactivities.
Bray RA; Lebeck LK; Gebel HM
Transplantation; 1989 Nov; 48(5):834-40. PubMed ID: 2815255
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous detection of antibody binding and cytotoxicity in flow cytometry crossmatch for renal transplantation.
Won DI; Jeong HD; Kim YL; Suh JS
Cytometry B Clin Cytom; 2006 Mar; 70(2):82-90. PubMed ID: 16470535
[TBL] [Abstract][Full Text] [Related]
13. Image cytometry as an alternative to flow cytometry for the transplant histocompatibility crossmatch assay.
Ramon DS; Franks T; Jaramillo A; Paradis BD; Chan LL
HLA; 2019 Jun; 93(6):436-444. PubMed ID: 30838802
[TBL] [Abstract][Full Text] [Related]
14. Pronase independent flow cytometry crossmatching of rituximab treated patients.
Alheim M; Wennberg L; Wikström AC
Hum Immunol; 2018 Feb; 79(2):132-135. PubMed ID: 29157993
[TBL] [Abstract][Full Text] [Related]
15. Impact of pronase on flow cytometric crossmatch outcome.
Hetrick SJ; Schillinger KP; Zachary AA; Jackson AM
Hum Immunol; 2011 Apr; 72(4):330-6. PubMed ID: 21262310
[TBL] [Abstract][Full Text] [Related]
16. Weak humoral posttransplant alloresponse after a well-HLA-matched cadaveric kidney transplantation.
Matinlauri IH; Kyllönen LE; Eklund BH; Koskimies SA; Salmela KT
Transplantation; 2004 Jul; 78(2):198-204. PubMed ID: 15280678
[TBL] [Abstract][Full Text] [Related]
17. Rapid optimized flow cytometric crossmatch (FCXM) assays: The Halifax and Halifaster protocols.
Liwski RS; Greenshields AL; Conrad DM; Murphey C; Bray RA; Neumann J; Gebel HM
Hum Immunol; 2018 Jan; 79(1):28-38. PubMed ID: 29109009
[TBL] [Abstract][Full Text] [Related]
18. Improved flow cytometry based cytotoxicity and binding assay for clinical antibody HLA crossmatching.
Alheim M; Paul PK; Hauzenberger DM; Wikström AC
Hum Immunol; 2015 Nov; 76(11):849-57. PubMed ID: 26429307
[TBL] [Abstract][Full Text] [Related]
19. The flow cytometric crossmatch and early renal transplant loss.
Mahoney RJ; Ault KA; Given SR; Adams RJ; Breggia AC; Paris PA; Palomaki GE; Hitchcox SA; White BW; Himmelfarb J
Transplantation; 1990 Mar; 49(3):527-35. PubMed ID: 2138366
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of the median channel shift in the flow cytometry for predicting complement dependent cytotoxicity crossmatching in kidney transplant candidates.
de Moraes P; Fagundes I; Cardone JM; Gil BC; Kulzer ASS; Hadi RA; Manfro RC; Jobim LF
Transpl Immunol; 2019 Feb; 52():27-31. PubMed ID: 30367965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
